Re-assessment of Cancer risk in Barrett’s oesophagus.

  • Fouad Yousef (Participant)
  • Christopher Cardwell (Participant)
  • Cantwell, Marie (Participant)
  • Karen Galway (Participant)
  • Liam Murray (Participant)
  • Lesley Anderson (Participant)
  • Suzanne Murphy (Participant)
  • Deirdre Fitzpatrick (Participant)
  • Brian Johnston (Participant)
  • Robert Watson (Participant)
  • Peter McCarron (Participant)
  • Gavin, Anna (Participant)
  • Shivaram Bhat (Participant)
  • Coleman, Helen (Participant)
  • Damian McManus (Participant)
  • Coleman, Helen (Participant)

Impact: Health Impact, Quality of Life Impact

Narrative

Research within the Northern Ireland Barrett’s oesophagus Register demonstrated that cancer risk in this disease was substantially lower than previously thought. It identified clinico-pathological characteristics and potential biomarkers that allow Barrett’s patients to be stratified into those with higher and lower cancer risk. This research has influenced recommendations from Gastroenterological Associations in the UK and USA and resulted in altered clinical practice nationally and internationally, in which costly routine endoscopic surveillance is now targeted to Barrett’s oesophagus patients with the highest cancer risk.

Impact statusOngoing
Category of impactHealth Impact, Quality of Life Impact